Recent News

• 04.07.2025 - Verrica Pharmaceuticals Reports Strong Demand-Led Growth in YCANTH® Dispensed Applicator Units in First Quarter 2025
• 04.07.2025 - Verrica Pharmaceuticals Reports Strong Demand-Led Growth in YCANTH® Dispensed Applicator Units in First Quarter 2025
• 04.07.2025 - Verrica Pharmaceuticals Reports Strong Demand-Led Growth in YCANTH® Dispensed Applicator Units in First Quarter 2025
• 04.02.2025 - Verrica Pharmaceuticals Appoints Gavin Corcoran, M.D. to its Board of Directors
• 04.02.2025 - Verrica Pharmaceuticals Appoints Gavin Corcoran, M.D. to its Board of Directors
• 04.02.2025 - Verrica Pharmaceuticals Appoints Gavin Corcoran, M.D. to its Board of Directors
• 03.31.2025 - Verrica Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference
• 03.31.2025 - Verrica Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference
• 03.31.2025 - Verrica Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference
• 03.26.2025 - Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D., as Chief Medical Officer

Recent Filings

• 04.02.2025 - 3 Initial statement of beneficial ownership of securities
• 04.02.2025 - 8-K Current report
• 04.02.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.26.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.26.2025 - 3 Initial statement of beneficial ownership of securities
• 03.25.2025 - EFFECT Notice of Effectiveness
• 03.18.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.18.2025 - 4 Statement of changes in beneficial ownership of securities